Thursday , May 24 2018
Home / Steve Freed, R.PH., CDE (page 3)

Steve Freed, R.PH., CDE

Steve Freed, R.PH., CDE
(Publisher Diabetes In Control) Stephen Freed, a registered pharmacist and diabetes educator, is the founder and publisher of Diabetes In Control. He is dedicated to advancing diabetes care for patients, physicians, pharmacists, and nurses. Steve has worked with many physicians helping them manage their diabetes patients. He has been president of the Chicago Chapter of the American Association of Diabetes Educators, is a certified pump trainer, and has developed and presented CE/CME programs for AADE.

390 Drugs That Can Affect Blood Glucose Levels

Knowing the drugs that can affect blood glucose levels is essential in properly caring for your diabetes patients. Some medicines raise blood sugar in patients while others might lower their levels. However, not all drugs affect patients the same way. The list includes: Drugs that may cause hyperglycemia Drugs that may cause hypoglycemia Drugs that may cause hyper or hypoglycemia Drugs that mask hypoglycemia

Read More »

Thomas Seck Current Interview

Thomas Seck is Vice President of US Clinical Development and Medical Affairs Primary Care at Boehringer Ingelheim. Thomas earned his medical degree from the University of Mainz in Germany. He completed his residency and fellowship within the Department of Endocrinology and Metabolism, at the University of Heidelberg, Germany.

Read More »

Thomas Seck Transcript

In this exclusive interview transcript, Thomas Seck discusses new data on the effect of Empagliflozin compared to standard of care for cardiovascular death, for hospitalization of heart failure, for overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids.

Read More »

Thomas Seck Full Interview

In this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about new data on the effects of Empagliflozin and how it compares to the standard of care in terms of cardiovascular death, overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids. 

Read More »